Figure 3.

Prognostic impact on overall patient survival of distinct gene amplification profiles of GBM patients from the test cohort – series 1 alone (n=76); panels (A) and (B) – and after pooling our cases with 181 additional cases from seven series of GBM patients previously reported in the literature by other groups (panels (C) and (D); n= 257 GBM). In panels (A) and (C), GBM patients were grouped as having i) no gene amplification; ii) isolated EGFR amplification; iii) gene amplification at multiple chromosomal regions including EGFR gene amplification; iv) isolated amplification of DNA sequences from a single chromosomal region other than 7p11.2 (i.e not including amplification of the EGFR gene), and; v) gene amplification at multiple chromosomal regions in the absence of EGFR amplification. In panels (B) and (D), patients were grouped as: i) cases showing either no gene amplification or having EGFR gene amplification and ii) patients showing genetic amplification at one or more chromosomal regions which did not involve the EGFR gene. Median overall survival is expressed in months and was calculated for 257 patients from series 1-8. Cases who were alive but had a follow-up of less than 18 months and/or died within the 1st month after surgery (n= 16) were excluded from OS analyses.